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Objective: Chondrocyte signaling is widely identiﬁed as a key component in cartilage homeostasis.
Dysregulations of the signaling processes in chondrocytes often result in degenerative diseases of the
tissue. Traditionally, the literature has focused on the study of major players in chondrocyte signaling,
but without considering the cross-talks between them. In this paper, we systematically interrogate the
signal transduction pathways in chondrocytes, on both the phosphoproteomic and cytokine release
levels.
Methods: The signaling pathways downstream 78 receptors of interest are interrogated. On the phos-
phoproteomic level, 17 key phosphoproteins are measured upon stimulation with single treatments of 78
ligands. On the cytokine release level, 55 cytokines are measured in the supernatant upon stimulation
with the same treatments. Using an Integer Linear Programming (ILP) formulation, the proteomic data is
combined with a priori knowledge of proteins’ connectivity to construct a mechanistic model, predictive
of signal transduction in chondrocytes.
Results: We were able to validate previous ﬁndings regarding major players of cartilage homeostasis and
inﬂammation (e.g., IL1B, TNF, EGF, TGFA, INS, IGF1 and IL6). Moreover, we studied pro-inﬂammatory
mediators (IL1B and TNF) together with pro-growth signals for investigating their role in chondrocytes
hypertrophy and highlighted the role of underreported players such as Inhibin beta A (INHBA), Defensin
beta 1 (DEFB1), CXCL1 and Flagellin, and uncovered the way they cross-react in the phosphoproteomic
level.
Conclusions: The analysis presented herein, leveraged high throughput proteomic data via an ILP
formulation to gain new insight into chondrocytes signaling and the pathophysiology of degenerative
diseases in articular cartilage.
 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Articular cartilage is a connective tissue covering the ends of
bones in a joint, responsible for bearing loads with minimumwear
and friction. Cartilage homeostasis is orchestrated by a complexL.G. Alexopoulos, Mechanical
ty of Athens, Athens, Greece.
s).
Center of Immunology and
the Academy of Athens, Ath-
s Research Society International. Pinterplay of anabolic and catabolic processes that take place in
chondrocytes. Chondrocytes are meant to maintain the structure of
the tissue by synthesizing collagen (mostly of type II) and pro-
teoglycans. However in pathological situations, they release matrix
metalloproteinases (MMPs) that degrade the collagen content of
the tissue, leading to loss of its structural integrity. Protein signaling
plays a central role to chondrocytes capability to either synthesize
cartilage and maintain its homeostasis, or degrade cartilage and
promote the inﬂammatory response seen in pathologic situations.
For example, up-regulation of the SOX9 transcription factor
induced by TGFB or FGF stimulation leads to collagen synthesis. On
the other hand, over-activation of NFKB induced by several path-
ways (e.g., Inﬂammation related pathways or bone developmentublished by Elsevier Ltd. All rights reserved.
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tion. Thus, chondrocytes have the potential for both anabolic and
catabolic roles in articular cartilage, and the role they eventually
assume is the one dictated by their signaling mechanisms as a
response to their biochemical microenvironment.
The importance of protein signaling in cartilage homeostasis has
been interrogated before, with most of the studies focusing on the
deconvolution of signaling processes in chondrocytes and the
identiﬁcation of catabolic mediators. Traditionally, most of these
approaches revolve around few major pathways (such as IL1A/B,
TNFA, TGFA/B, etc.), without taking into account other less known
players. Considering that chondrocyte function and response re-
sults as an aggregate of numerous processes and that even the
slightest crosstalk can eventually affect cell behavior, the system-
atic study of chondrocytes signaling is of the utmost importance for
uncovering the etiology of degenerative diseases and facilitate the
development of novel therapies8e11. To this end, high throughput
proteomic measurements combined with computational modeling
offer a promising solution. Proteomics technologies allow the
multiplexed quantiﬁcation of proteins, while computational
modeling post-processes the results in a way that interpretable
conclusions can be extracted for the interrogated system.
Proteomics have been used in the study of degenerative diseases
of cartilage in the past, addressing mostly the following: (1) direct
analysis of cartilage protein content12e15, (2) analysis of cartilage
related biological ﬂuids16,17 (Synovial ﬂuid) and (3) study of chon-
drocytes secretion upon treatment with catabolic mediators18,19. In
more detail, proteomic analysis of cartilage explants and chon-
drocytes has lead to the identiﬁcation of hundreds of proteins in
articular cartilage, as well as characterization of their expression
patterns in normal (control) and disease patients. Findings of this
analysis lead to better understanding of the etiology underlying
degenerative diseases and potential drug targets. Study of chon-
drocyte secretory behavior may lead to deeper understanding of
the cells’ plasticity to mount and overcome an inﬂammatory
response; while proteomic analysis of the synovial ﬂuid and plasma
has identiﬁed proteins differentially regulated in normal and dis-
ease patients, and aims mostly at biomarker discovery.
The applications of proteomics mentioned above, form the basis
towards a systems-level understanding of the processes taking
place in chondrocytes; however, they do not interrogate their
signaling mechanisms. To study chondrocytes signaling, phospho-
proteomic data must also be incorporated and by implementing a
mathematical formalism to model how signal propagates from one
protein to the next, construct predictive models of their function.
In this paper, we interrogate the signal transduction mecha-
nisms of primary chondrocytes on both the phosphoproteomic and
the cytokine release levels upon stimulation with 78 ligands,
including some major players of osteoarthritic pathophysiology, as
well as ligands well characterized for promoting inﬂammation in
other cells types. Our approach is two-fold. On the experimental
front we use the xMAP technology to measure the activation level
of 17 key phosphoproteins and the release of 55 cytokines in the
cells’ supernatant, upon stimulation with single treatments of the
78 ligands. Even though the xMAP technology does not provide for
signal multiplexability as high as other proteomic technologies, fast
turnaround times using the Luminex equipment and low re-
quirements in protein content allows the design of the experiment
on 96-well plates, leading to high sample-throughput20,21. On the
computational front, an Integer Linear Programming (ILP) formu-
lation is used to ﬁt a prior knowledge network (PKN) to the pro-
teomic data, resulting in a mechanistic model, predictive of the
function and response of human chondrocytes22. The proposed ILP
approach is based on Boolean logic to model signal transduction in
the network. Boolean logic assumes protein activation can takeonly binary values (ON/OFF) and then uses Boolean gates (AND/OR/
NOT) to model protein connectivity in the signaling network. By
adopting Boolean logic and using a PKN e obtained from literature
citations of signaling reactions e as a scaffold, we construct an
initial model of the signal transduction network. Subsequently, the
ILP formulation is used to train this model to the proteomic data, by
removing reactions that contradict the data at hand. In this manner,
the optimized model best captures the signaling patterns of human
chondrocytes.
Methods
Chondrocyte isolation, culture and stimulation
Cartilage tissue was obtained from the femoral heads of patients
undergoing total hip arthroplasty because of subcapital femoral
fractures. Tissue was isolated using standard methods. Chon-
drocytes were isolated by sequential enzymatic digestion with
pronase for 15 min at 37C and 0.4% collagenase Type II for 4 h at
37C as previously reported23. Enzymes were diluted in serum-free
Dulbecco’s modiﬁed Eagle’s medium supplemented with 50 mg/ml
gentamycin, 100 mg/ml Kanamycin and 1.25 mg/ml Fungizone
Amphotericin B. Isolated chondrocytes were washed, strained with
70 mm nylon meshes, and ﬁnally seeded at high-density
(50,000 cells/well) in 96-well plates resuspended in DMEM
high glucose, supplemented with 10% FBS, 100 U/ml Penicillin
Streptomycin, 10 mM HEPES and 1% MEM Non-essential Amino
Acids Solution. Cells were cultured for 24 h (60% conﬂuency) and
were then starved overnight at 37C, 5% CO2, in serum-free DMEM
high glucose; stimulated with single treatments of 78 ligands (see
Supplementary Material 1) and were ﬁnally lysed at 5 and 25 min
after stimulation. The lysates were pooled in a 1:1 ratio before
executing the Luminex assay. The library of 78 ligands was
compiled to include some (but not all) of the major players of
cartilage biology together with many underreported ligands, in an
attempt to discover new players of cartilage pathophysiology.
Samples from various donors were used for developing the
experimental protocols and for preliminary studies. However, the
computational analysis that follows requires minimum biological
variation for maximum signal to noise ratio; thus, for the ﬁnal
experiment only samples from a single donor were considered. We
expect donor to donor variability, but that should be in the same
levels as with previous studies21.
Luminex assay
Phosphoproteins
A Luminex 200 systemwas used, to measure the activation of 17
phosphoproteins (AKT, JUN, CREB, ERK, GSK3, HISTH3, HSP27, IKB,
IRS1S, JNK, MAP2K1, MAPK14, TP53, RPS6KB1, RPS6KA1, STAT3,
STAT6) 5 and 25 min after stimulation, as described in21. The 17
phosphoproteins were chosen based on assay availability and
quality controls performed at early stages of the experimental
setup.
Cytokine releases
A library of 55 cytokine releases including most major inﬂam-
matory mediators such as cytokines, chemokines, growth factors,
as well as degenerative enzymes (MMPs) (CCL27, CCL11, FGF2, CSF3,
CSF2, CXCL1, HGF, ICAM, IFNA2, IFNG, IL10, IL12, IL12P40, IL13, IL15,
IL16, IL17, IL18, IL1B, IL1RA, IL2, IL2R, IL3, IL4, IL5, IL6, IL7, IL8, IL9,
CXCL10, LIF, CCL2, CCL7, CSF1, MIF, CXCL9, CCL4L1, CCL4L2, NGF,
PDGFB, CCL5, KITLG, SCGFB, CXCL 12, TNF, LTA, TNFSF 10, VCAM1,
VEGF121, MMP1, MMP10, MMP13, MMP3, MMP8, MMP9) was
measured in the supernatant 24 h after stimulation.
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Both phosphoprotein and cytokine release data are measured in
ﬂuorescent units and is dependent on the antibody pair used for
detection. For instance, MAP2K1 ranged from 280 units (untreated
condition) to 6500 units (under EGF), while GSK3 ranged from 500
units (untreated condition) to 1500 units. Variations such as these
do not necessarily reﬂect that MAP2K1 is more activated than
GSK3, but may be attributed to protein abundance or assay cali-
bration issues. Consequently two challenges emerge, ﬁrstly, iden-
tifying whether a signal is activated or not, and secondly,
normalizing the raw data in a way that the optimization algorithm
is not biased in favor of the highest values24. Herein we imple-
mented the normalization procedure introduced in25: We ﬁtted the
measurements of each signal to a bimodal distribution and for each
datapoint, we formed the ratio of the frequencies with respect to
the twomodes and passed it to a hill function tomap it to [0,1]. The
normalized data were used by the ILP algorithm.Construction and pre-processing of the PKN
A PKNwas constructed downstream the 78 receptors of interest,
based on literature citations of signaling reactions25. Several online
databases were queried (Reactome26, PathwayCommons27,
KEGG28), but most of the reactions were obtained from Ingenuity
(http://www.ingenuity.com/). The PKN was constructed in such a
manner that it includes all interrogated receptors and measured
phosphoproteins.
Upon its construction, the PKN was preprocessed to remove
non-observable and non-controllable parts of it according to24.
Non-observable, are nodes in the pathway whose activation state
cannot be inferred based on the measured phosphoproteins (i.e.,
Nodes, downstream of which there are no measured signals). Non-
controllable are nodes whose activation state cannot be controlled
by the imposed perturbations (i.e., Nodes with no upstream stim-
uli). Removing non-observable, non-controllable parts of the
pathway facilitates the optimization process by reducing the size of
the pathway.Optimization of signaling pathways to proteomic data via an
ILP formulation
An ILP formulation was used to ﬁt the PKN to proteomic data by
removing reactions that contradict the data at hand. See also22.
Assume a signaling network G deﬁned as a set of reactions
i ¼ 1,., nr and species j ¼ 1,.,ns. Each reaction i is described by
three index sets; the set of reactants Ri, the set of inhibitors Hi and
the set of products Pi; Ri, Hi, Pi 3 {1,.,ns}. We also deﬁne a set of
experiments k ¼ 1,.,ne. In each experiment k a set of species Ikj are
perturbed with Ikj ˛f0;1g; j ¼ 1; .;ns; k ¼ 1;.;ne. Ikj ¼ 1 if
species j in experiment k is set to active (ON); Ikj ¼ 0 if j is not
perturbed. Moreover, we deﬁne variables xkj ˛f0;1g to denote the
predicted activation state of species j in experiment k. xkj ¼ 1 if
species j is active in experiment k; xkj ¼ 0 otherwise. If species j is
also measured and it is found to be active in experiment k, then
xk;mj ¼ 1, else if it is found to be inactive x
k;m
j ¼ 0. We also intro-
duce variables zki ˛f0;1g; i ¼ 1;.;nr; k ¼ 1;.;ne to denote
whether reaction i is active ðzki ¼ 1Þ or not ðzki ¼ 0Þ in experiment
k. Finally, we deﬁne variables yi˛f0;1g; i ¼ 1;.;nr to denote
whether reaction i is present in the network. yi ¼ 1 if reaction i is
present in the network; yi ¼ 0 otherwise.Starting from the perturbed nodes, the signal is propagated
downstream following the rules of Boolean logic. Thus,
1. A reaction iwill take place in experiment k ðzki ¼ 1Þ if and only if
it is present in the network (yi¼ 1), all reactants are present (i.e.,
xkj ¼ 1; cj˛Ri) and no inhibitors are present (i.e.,
xkj ¼ 0; cj˛Hi).
2. If a reaction i takes place all downstream species will be acti-
vated (i.e., xkj ¼ 1; cj˛Pi; k ¼ 1;.;ne)
3. A species j will be active (i.e., xkj ¼ 1) if and only if a reaction i
takes place (i.e., zki ¼ 1) where this species is a product (i.e.,
j˛Pi); otherwise j will be inactive (i.e., xkj ¼ 0).
The rules above may be formulated as linear constraints in the
following manner:
xkj  Ikj ; j ¼ 1;.;ns; k ¼ 1;.;ne
zki  xkj ; cj˛Ri; i ¼ 1;.;nr ; k ¼ 1;.;ne
zki  1 xkj ; cj˛Hi; i ¼ 1;.;nr ; k ¼ 1;.;ne
zki  yi þ
P
j˛Ri

xkj  1

 P
j˛Hi

xkj

; i ¼ 1;.;nr; k ¼ 1;.;ne
xkj  zki ; cj˛Pi; i ¼ 1;.;nr ; k ¼ 1;.;ne
xkj 
P
i¼1;.;nr :j˛Pi
zki þ Ikj ; j ¼ 1;.;ns; k ¼ 1;.;ne
(1)
The aim of the formulation is to identify the optimal values of yi
variables to minimize the mismatch between experimental data
and model predictions. Additionally, because a number of solutions
may exist with the same optimal objective value, the size of the
solution is also minimized to harvest the one incorporating the
fewest reactions see also22. Thus, the following objective function is
used.
X
j;k
akj
xkj  xk;mj
þ
X
i
biyi (2)
Equations (1) and (2) deﬁne an ILP, where (1) are the constraints
of the formulation and (2) is the objective function to be mini-
mized. The ILP is solved using Gurobi29 under GAMS30 (General
Algebraic Modeling System, http://www.gams.com/). Finally, vari-
ables xkj and z
k
i may be relaxated to [0, 1] to speed up the optimi-
zation procedure without affecting the optimal solution, see22.Results
Phosphoproteomic level
Phosphoproteomic measurements
Chondrocytes were stimulated with single treatments of 78 li-
gands while measuring the activation level of 17 key phospho-
proteins via xMAP technology. The phosphoproteomic dataset is
plotted in Fig. 1 via DataRail toolbox31. Fig. 1 is a collection of sub-
plots representing the time course of the 17 signals from the
unstimulated state to the average early response under each of the
imposed ligands. The ﬁlling color in each subplot corresponds to
the normalized value of the signal. Activated signals are plotted in
red.
As shown in Fig. 1, a large number of stimuli raised a signiﬁcant
response in chondrocytes, activating at least one phosphoprotein
signal. As positive control observations, well known players such as
IL1B, TNF, EGF, TGFA, INS, IGF1 and IL6 responded as expected from
previous studies. The pro-inﬂammatory mediators IL1B and TNF
Fig. 1. Phosphoproteomic data: The time course of the phosphoprotein signals from the unstimulated state to the average early response is illustrated. The rows correspond to the
17 phosphoproteins measured and the columns to the 79 ligand treatments (including the No-ligand treatment). In each subplot, the ﬁrst point shows the unstimulated activity of
the respective signal (zero time point); the second point shows the raw measurement of the signal (in ﬂuorescent units) 5 þ 25 min after stimulation; while the color code
corresponds to the normalized value (between 0 and 1) of the signal. The numbers on the right hand side of the ﬁgure show the maximum phosphorylation value of each signal in
ﬂuorescent units.
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promote inﬂammation in cartilage, together with pro-growth sig-
nals such as CREB, ERK, GSK3, IRS1 and MAP2K1 (MEK12), vali-
dating their role in chondrocyte hypertrophy32. On the other hand,
pro-growth stimuli such as EGF, TGFA and INS activated only
anabolic pathways, leaving inﬂammation related signals unaf-
fected. Apart from the major players, a number of underreported
stimuli are found to affect chondrocytes signaling including INHBA
(Inhibin beta A), ADIPOQ (Adiponectin), DEFB1 (Defensin beta 1),
BTC (Betacellulin), CXCL1, HBEGF, IL19, CXCL10, ODN2006 (Toll Like
Receptor (TLR)9 ligand), NOG (Noggin) and Flagellin. A detailed
description of the screened stimuli and their role in cartilage
physiology is given in Supplementary Material 1. See also the Dis-
cussion section.Pathway construction based on the ILP formulation
The ILP formulation is used to train the PKN to the phospho-
proteomic data of Fig. 1, resulting in an integrative model, predic-
tive of the signal transductionmechanisms of human chondrocytes.
In more detail, the formulation removed all reactions from the PKN
that contradicted the data at hand in an attempt to minimize the
difference between model predictions and experimental data. The
optimized network is shown in Fig. 2. With thick black edges we
plotted the reactions that are validated by the data and with gray
edges the reactions that contradicted the data and were removed
by the ILP algorithm. An in depth analysis of the ILP performance
and experimental validation of model predictions in the neigh-
borhood of MAPK14, HSP27 and IKB signals is shown in
Supplementary Material 2.Fig. 2 validates the key ﬁndings of Fig. 1 and previous reports in
the literature: Major inﬂammatory mediators such as IL1B and TNF,
signal through their receptors to IKB, MAPK14, HSP27 and JUN. IL1B
also activates CREB and MAP2K1 (growth related signals) via
TRAF6, in good accordance to the phosphoproteomic data of Fig. 1
and the literature33. Pro-growth stimuli such as TGFA, BTC, EGF,
IGF1, INS and FGF2 signal through GRB2 to SOS, RAS and from there
either to MAP2K1 (MEK12) via RAF1, or signal through PI3K to AKT
and to CREB. IL6 activates mostly STAT3 via JAK1. On the other hand,
the signaling pathways of CXCL1, HBEGF, DEFB1, Flagellin and
INHBA were uncovered for the ﬁrst time in chondrocytes. CXCL1, a
small cytokine of the CXC family, binds to CXCR2 and activates
RPS6KA1. HBEGF, a ligand of the EGFR, signals via the same path-
ways as EGF, BTC and TGFA. DEFB1, a TLR ligand, signals through
TLR4 to RAC1 and from there to the MAPKs and ﬁnally activates
HSP27 demonstrating pro-inﬂammatory action. Flagellin, also a TLR
ligand, signals through TLR5 to MYD88 and then merges with the
IL1 pathway activating major inﬂammatory signals, CREB and
MAP2K1. INHBA, a ligand of the TGFBR, signals via the MAPKs to
activate JNK and P53.Experimental validation of the HSP27, MAPK14, and IKB
connectivity in the solution
To validate the results of the ILP formulation, we chose a
neighborhood of the optimized network and performed follow up
experiments; this is the neighborhood around the HSP27, MAPK14
and IKB signals. As shown in Fig. 2, HSP27, MAPK14 and IKB are
activated by two pathways that overlap at NIK, one originating from
IL1B and Flagellin that signals via IRAK, TIFA, TRAF6 and NIK, and a
Fig. 2. Optimized pathway: The signal transduction network upon optimization via the ILP formulation. Green rectangular nodes correspond to the imposed ligands, gray elliptic nodes to the measured phosphoproteins, gray rectangle
nodes to the measured cytokine releases and clear (white) elliptic nodes to latent signaling proteins in the network. The optimization procedure trains the PKN by removing reactions that contradict the proteomic data at hand. Thick
black edges denote the reactions validated by the data; gray edges denote the reactions that contradicted the data and were removed by the ILP algorithm.
I.N
.M
elas
et
al./
O
steoarthritis
and
Cartilage
22
(2014)
509
e
518
513
Fig. 3. Cytokine release data: The time course of the cytokine releases from the unstimulated state to 24 h is illustrated. The rows correspond to the 55 cytokine releases measured in the supernatant and the columns to the 79 ligand
treatments (including the No-ligand treatment). In each subplot, the ﬁrst point shows the unstimulated concentration of the respective cytokine in the supernatant (zero time point); the second point shows the raw measurement of
the signal (in ﬂuorescent units) 24 h after stimulation; while the color code corresponds to the normalized value (between 0 and 1) of the signal. The numbers on the right hand side of the ﬁgure show the maximum phosphorylation
value of each signal in ﬂuorescent units.
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A B
Fig. 4. Effects of the MAPK14 and PI3K inhibition on the activity of IKB and HSP27 upon stimulation with IL1B and TNF: Inhibition of MAPK14 clearly decreases HSP27 activity upon
IL1B and TNF stimulation, validating that HSP27 is activated in a MAPK14 dependent manner, in good accordance to model predictions. IKB activity is not blocked neither by
MAPK14 nor PI3K inhibition validating that IKB is activated by an independent pathway. The numbers on the left correspond to the raw phosphorylation value of the measured
signals in ﬂuorescent units.
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and NIK. Then, from NIK a pathway activates IKB via IKBKB and
another activates MAPK14 and HSP27 viaMAP2K6 and MAPKAPK5
(node “OR” is an auxiliary node). Note that HSP27 is downstream of
MAPK14, while it is also activated by an independent pathway via
MAPK11, MAP2K4, MAP3K5 and RAC1, but this pathway is only
functional under the DEFB1 stimuli. For the rest of the stimuli (IL1B,
Flagellin, TNF), HSP27 is activated via MAPK14.
As a follow up experiment we perturbed the cells with major
activators of HSP27, MAPK14 and IKB signals, in combination with
small molecular inhibitors to block key signaling proteins, while
monitoring HSP27 and IKB activation in an attempt to validate the
connectivity of these three nodes in the solution. As activators we
used IL1B and TNF. (1) IL1B to stimulate the ﬁrst pathway to NIK
and (2) TNF to stimulate the second pathway to NIK as described
above. As inhibitors we used a potent MAPK14 inhibitor (PHA-
818637 at 100 nM) and a PI3K inhibitor (PI-103 at 10 mM). The
activation of HSP27 and IKB was measured at three time points (5,
15 and 25 min), using the Luminex xMAP technology as described
in the Methods section. Results are plotted in Fig. 4.
Fig. 4(A) shows how the inhibition of MAPK14 affects HSP27. In
good accordance tomodel predictions, inhibitionofMAPK14 caused a
signiﬁcant decrease of HSP27 activation, since the ILP placed the
HSP27 signal directly downstream ofMAPK14. Note that in the initial
network (gray edges in Fig. 2) a number of alternative pathways are
included for HSP27 activation upon stimulation with IL1B and TNF
that do not go through MAPK14 (e.g., IL1B/ IL1R2/ IRAK/ TIFA
/ TRAF6/ MAP3K5/ MAP2K4/ MAPK11/ MAPKAPK5/
HSP27, orTNF/TNFRSF1B/TRAF2/NIK/MAP2K3/MAPK11
/ MAPKAPK5/ HSP27), however, these were removed by the ILP
algorithm as non-functional in the interrogated cell type, and HSP27
was placed directly downstream of MAPK14. On the other hand, the
inhibition of PI3K had no effects on HSP27 activation, also in good
accordance tomodel predictions, where theMAPK14, HSP27 and IKB
pathway is completely disconnected from PI3K. Finally, Fig. 4(B)
shows how IKB activity is affected byMAPK14 and PI3K inhibition. In
good accordance to model predictions, IKB is not affected by either
MAPK14 or PI3K inhibition, since IKB is regulated by a different
pathway thanMAPK14 and is also disconnected from PI3K. Thus, the
follow up experiments of Fig. 4 validate the connectivity of HSP27,
MAPK14 and IKB in the optimized network.Cytokine release level
Chondrocytes were stimulated with single treatments of 78 li-
gands while measuring the release of 55 cytokines. The cytokinerelease data is shown in Fig. 3. Fig. 3 is a collection of subplots
representing the time course of the 55 signals from the unstimu-
lated state to 24 h, for each of the imposed ligands. The ﬁlling color
in each subplot corresponds to the normalized value of the signal.
As shown in Fig. 3, a large number of the imposed stimuli pro-
moted signiﬁcant cytokine release in chondrocytes. The strongest
inducers were FSTL1 (a TLR 6/2 agonist), GDF5, HKSA (TLR2 ligand),
IL1A, IL1B, IL6, LPS, PAM3CSK4 (TLR 1/2 agonist), POLYIC (TLR3
agonist), Flagellin (TLR5 agonist), TNF and LTA (a member of the
TNF superfamily). Most of them have already been proven to
exhibit pro-inﬂammatory action; however, there are a number of
underreported players such as GDF5 and LTA. As positive controls,
we observe that major inﬂammatory mediators such as IL1A and
IL1B raised an extensive inﬂammatory response inducing the
release of most of the measured cytokines. Moreover, IL1A, IL1B
together with many of the inﬂammatory mediators mentioned
above were found to induce the release of MMPs (mainly MMP13
and MMP1) known to degrade the collagen content of the tissue.
Finally, we observe that pro-growth stimuli did not induce any
signiﬁcant cytokine releases.Discussion
In this paper, we have presented a rigorous approach for the
study of signal transduction in chondrocytes on a systems level. We
interrogated their signalingmechanisms, downstream 78 receptors
of interest, on both the phosphoproteomic and the cytokine release
levels and also employed an ILP formulation to construct a pre-
dictive model of their signaling processes. On the experimental
front, we adopted the xMAP technology to measure 17 key phos-
phoproteins and the release of 55 cytokines in the supernatant,
upon stimulation with single treatments of the 78 ligands. These
ligands were selected to stimulate major osteoarthritic degradation
pathways. On the computational front, we implemented an opti-
mization formulation, based on themodeling of signal transduction
via Boolean logic, to train a PKN to the proteomic data by removing
reactions that appear not to be functional in primary chondrocytes.
The analysis presented herein, was able to validate previous
ﬁndings regarding major players of cartilage homeostasis and
inﬂammation (e.g., IL1B, TNF, EGF, TGFA, INS, IGF1 and IL6); high-
light the role of underreported players such as INHBA, DEFB1,
CXCL1 and Flagellin in chondrocyte signaling; identify their
signaling pathways, and uncover the way they cross-react in the
phosphoproteomic level. Even though most of the effects of the
interrogated stimuli on the measured phosphoproteins or cytokine
releases have been reported before, this is the very ﬁrst attempt to
I.N. Melas et al. / Osteoarthritis and Cartilage 22 (2014) 509e518516our knowledge to leverage high throughput proteomic data via a
bioinformatics approach, and identify which of the signaling
pathways reported in literature are functional in primary human
chondrocytes and orchestrate their response to external pertur-
bations. On this front regarding the underreported players DEFB1
and Flagellin: We identiﬁed that DEFB1 signals via its receptor to
RAC1, to the MAPKs and ultimately activates HSP27. Flagellin sig-
nals through TLR5 toMYD88 and thenmerges with the IL1 pathway
signaling through IRAK, TIFA, TRAF6 and activates the IKB, MAPK14
and HSP27 signals. Moreover, we were able to validate part of the
DEFB1 and Flagellin pathways in the neighborhood around the
MAPK14, HSP27 and IKB signals via an independent follow up
experiment (see Supplementary Material 2), proving the predictive
power of the proposed ILP algorithm and reliability of model pre-
dictions. On the other hand, the lack of data in the remaining part of
these pathways implies the ambiguity of the solution from the TLRs
to the neighborhood of MAPK14, HSP27 and IKB, requiring tedious
follow up experiments to validate that exceeds the scope of this
work. Below we discuss our ﬁndings in the context of degenerative
diseases such as osteoarthritis (OA).
Inﬂammatory mechanisms
OA has a strong inﬂammatory component4. Our analysis of
cytokine release data (see Fig. 3) extensively validates the role of
chondrocytes in inﬂammation: In Fig. 3, chondrocytes are found to
release cytokines and MMPs upon stimulation with major inﬂam-
matory mediators (IL1B and TNF), in good accordance to literature
reports; but also upon stimulation with underreported ligands.
Moreover, taking into account that the tissues used for our analysis
came from healthy donors, our ﬁndings suggest even healthy cells
have the potential to demonstrate a strong inﬂammatory response
(rather than protective). In this manner, the generation of an in-
ﬂammatory environment in the joint is facilitated and given that
cartilage is an avascular tissue, lacking important anti-
inﬂammatory components of peripheral blood34, this environ-
ment is sustained, eventually leading to the degradation of the
tissue.
The inﬂammatory mechanisms of chondrocytes were also
studied on the phosphoproteomic level. Using an ILP formulation22,
for the ﬁrst time wewere able to identify the signaling pathways of
underreported pro-inﬂammatory mediators such as DEFB1 and
Flagellin (TLR ligands). Even though the role of TLR in cartilage
inﬂammation has been studied before, this is the ﬁrst attempt to
identify the signaling events that lead to the up-regulation of NFKB,
HSP27 and other pro-inﬂammatory signals upon stimulation of the
TLR. In more detail, two major inﬂammatory pathways were un-
covered: the ﬁrst activating IKB via NIK, and the second activating
HSP27 via MAPK11 and MAPK14 dependent mechanisms. More-
over, cross-talks of the TLRwith other major inﬂammatory and pro-
growth pathways were uncovered.
Chondrocyte hypertrophy and proliferation
During OA, proliferation and hypertrophic differentiation of
chondrocytes occur. These processes resemble to skeletal devel-
opment by endochondral ossiﬁcation mechanisms35. They refer to
the gradual differentiation of chondrocytes and subsequent release
of BMPs that leads to matrix remodeling. Our analysis of the
phosphoproteomic data sheds light into thesemechanisms. As seen
in Fig. 1, stimulation with IL1B and Flagellin (two major inﬂam-
matory mediators) apart from up-regulation of inﬂammatory sig-
nals, also leads to over-activation of CREB andMAP2K1, two growth
related signals that are connected to hypertrophy36,37 (IL1B also
activates ERK, GSK3 and IRS1 but this is not shown in the network).The mechanism of CREB and MAP2K1 activation was uncovered by
the ILP algorithm and is shown in the network of Fig. 2. IL1B and
Flagellin signal through overlapping pathways to IRAK, TIFA and
then to TRAF6. From TRAF6 either activate pro-inﬂammatory sig-
nals, or go through RAC1 to activate CREB and MAP2K1.
Moreover, inspection of the cytokine release data of Fig. 3 re-
veals another potential mechanism IL1B and Flagellin induce
chondrocyte hypertrophy: Both IL1B and Flagellin induce the
release of FGF2 known to play a role in endochondral ossiﬁcation35
and CXCL1, a chemokine that induces chondrocyte hypertro-
phy38,39. IL1B additionally induces the release of CSF3 (another pro-
growth factor). Thus, IL1B and Flagellin apart from directly acti-
vating pro-growth signals via the pathways discussed above, also
lead to the release of pro-growth cytokines, facilitating chon-
drocyte hypertrophy and bone ossiﬁcation indirectly.Innate immune response in OA TLR signaling
The role of TLR signaling in OA is becoming of increasing sig-
niﬁcance as the community attempts to identify the etiology un-
derlying the pathogenesis of the disease. TLRs belong to the family
of pattern-recognition receptors and play a pivotal role in the
activation of the innate immune system in response to invading
microbial components40. TLR stimulation elicits strong release of
pro-inﬂammatory cytokines41; while only recently human articular
chondrocytes were shown to express TLRs42,43. In this paper we
addressed TLR signaling extensively by screening 10 TLR ligands
(DEFB1, HKSA, Imiquimod, Flagellin, LPS, ODN2006, PAM3CSK4,
POLYIC, SSRNA40 and FSTL1). On the cytokine release level 6 of
them (FSTL1, HKSA, LPS, PAM3CSK4, POLYIC and Flagellin) were
found to raise a strong inﬂammatory response, validating the sig-
niﬁcance of TLR stimulation in joint inﬂammation. However, on the
phosphoproteomic level only DEFB1 and Flagellin signaled through
pathways monitored by the 17 phosphoprotein signals. DEFB1
signaled via TLR4 to RAC1 and from there to the MAPKs, eventually
activating HSP27. Flagellin signaled via a pathway overlapping with
IL1B and as discussed above, activated most inﬂammatory signals
together with MAP2K1 and CREB.
Overall, the proposed approach successfully addressed the
construction of a predictive model of the signaling mechanisms in
human chondrocytes. We interrogated signal transduction on both
the phosphoproteomic and cytokine release levels, upon stimula-
tion with 78 factors of interest, including most major players of
osteoarthritic pathophysiology, as well as ligands important for
other cell types. Our analysis validated previous ﬁndings in chon-
drocytes signaling, elucidated the role of underreported players
and identiﬁed cross-talks on the phosphoproteomic level, high-
lighting the pleiotropic role of major players in cartilage homeo-
stasis and inﬂammation.Author contributions
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